LINCOLN, R.I.óMultiCell Technologies Inc., an adult stem cell company and supplier of immortalized non-tumorigenic human hepatocytes for drug discovery, announced today that it has appointed Anthony Altig to the company's board of directors.
Altig has extensive experience in financial management, strategic planning and SEC reporting, as well as investor relations, budgeting, treasury, tax planning and risk management. His 23 years of experience with biotech and technology companies include public and debt financing transactions, financial operations, strategic alliances, mergers and acquisitions. Altig is currently Senior Vice President and chief financial officer for Diversa Corp. a leader in applying proprietary genomic technologies for the rapid discovery and optimization of novel protein-based products. Altig previously was the chief financial officer of Maxim Pharmaceuticals Inc.